不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
一名 SARS-CoV2 患者的慢性淋巴细胞白血病自发缓解
英文原题：Spontaneous remission of chronic lymphocytic leucemia in a patient with SARS-CoV2.
查看英文原题
Spontaneous remission of chronic lymphocytic leucemia in a patient with SARS-CoV2.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管新型疗法改善了患者的治疗结局，慢性淋巴细胞白血病（CLL）仍被认为无法治愈。最近，一种新型冠状病毒——严重急性呼吸综合征冠状病毒2（SARS-CoV2）——于2019年末出现，引起2019冠状病毒病（Covid 19），并对全球健康构成威胁。在有限数量的病例中，已显示某些淋巴瘤类型在SARS-CoV2感染后自发消退，提示该感染可触发免疫系统对抗肿瘤细胞。病原体特异性T细胞与肿瘤抗原的交叉反应以及NK 细胞活化可能是这一假说的可能机制。
展开英文摘要原文
Although novel therapies have improved the treatment outcome of patients, chronic lymphocytic leukaemia (CLL) is still considered incurable. Recently, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), causing coronavirus disease 2019 (Covid 19), emerged in late 2019, and it has posed a global health threat.
In a limited number of cases, it has been shown that some lymphoma types spontaneously regress after SARS-CoV2 infection suggesting that the infection can trigger de immune system against the tumour cell. Cross-reactivity of pathogen-specific T cells with tumour antigens and natural killer cell activation can be the possible mechanism of this hypothesis.
论文信息
- 作者
- Bülbül H、Nazlı HE、Olgun A、Togay A、Kahraman DS
- 第一作者单位
- Hematology Department, Tepecik Training and Research Hospital, Yenisehir, Konak/İzmir, Turkey.Turkey
- 通讯作者单位
- Pathology Department, Tepecik Training and Research Hospital, Yenisehir, Konak/İzmir, Turkey.Turkey
- 文献类型
- 病例报告
- 期刊
- Leukemia research reports2022
- 原文标识
- PubMed 35789744 · DOI 10.1016/j.lrr.2022.100336
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →